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Case report:
Clinical case of Carpenter syndrome (autoimmune-polygundularsyndrome 2) in the practice of an 
endocrinologist
        Pasiechko Nadiya1, Naumova Lyudmyla2, Pankiv Ivan3, Krytskyy Taras4, Khomits Alla5
Absrtact:
Presentation of case:	patient	36	years	old,	appealed	to	complaints	about	changing	the	color	of	the	skin,	
reducing	 body	weight	 by	 10	 kg	 in	 2	months,	 expressed	 general	 weakness,	 lowering	 blood	 pressure,	
reducing sexual desire. Discussion:	 prescribed	 treatment:	 insulin	 therapy	 (aspart,	 degludec)	 day	
dose	 	 42	OD,	 levothyroxine	 100	mcgr/day,	 vitamin	 E,	 selenium	 100	mcgr,	 chorionic	 gonadotrophin	
1500	OD	intramuscularly	once	per	week,	monthly	courses	with	the	same	break.	After	the	therapy,	the	
patient’s	condition	improved.	Repeatedly	the	patient	appeared	on	the	review	6	months	after	treatment.	
Hyperpigmentation	of	the	skin	and	natural	areas	of	pigmentation	are	reduced,	there	is	a	stabilization	of	
blood	pressure	at	a	level	of	120	/	70-110	/	70	mm	Hg,	reduction	of	clinical	symptoms,	achieved	target	level	
of	glycemia	and	hormonal	blood	parameters	the	target	glycemia	level	was	reached	(4.6-5.1	mmol	/	L),	
glycosylated	hemoglobin	(8.1%)	and	hormonal	blood	parameters	(TTG	3.4	mmol	/	L)	cortisol	serum	1.7	
μg	/	dl	(norm	6.2-19.4	μg	/	dl),	testosterone	free	3.4	pg	/	ml	(N	1.7-8.2),	total	testosterone	-	12.28	(N	8.64	
-	29	nmol	/	l),	sex	steroid	binding	globulin	(CHD)	(67	nmol	/	l,	at	the	rate	of		13-71	nmol	/	l,	),	testosterone	
free	8.9	pg	/	ml	(N	8.8	-	42.5	pg	/	ml). Conclusions:	Decomposition	of	adrenal	insufficiency	(decrease	in	
glucocorticoids	as	contrinsular	hormone)	can	lead	to	untypical	cours	of	diabetes	with	steaolyhipoglicemia	
in	autumne-summer	period	and	normalizabionglycemia glycemia	in	winter-autumne	period.	Presents	of	
2-3	decompensate,	endocrine	diseases	in	the	same	moment	suppresses	pronounced	typical	symptomatics	
each	of	them	precedes	with	erased	or	disguised	picture.
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hypogonadism.
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Presentation of case:
Today,	in	the	practice	of	endocrinologists,	ever	more	
common	is	 the	combined	endocrine	pathology.	The	
most	common	endocrinopathies	include	autoimmune	
polyglandular	 syndromes	 (APGS)	 that	 are	
characterized	 by	 primary	 damage	 to	 the	 endocrine	
glands.	 Then	 in	 most	 cases,	 glands’	 functional	
deficiency	is	formed,	which	is	often	combined	with	
autoimmune genesis diseases of other organs and 
systems1-2.
Today	 the	most	 common	 is	APGS-2,	 characterized	
by	 endocrine	 glands	 defeat	 with	 the	 development	
of	 primary	 hypocorticism,	 autoimmune	 thyroiditis	
(AIT),	diabetes	mellitus	type	1	(DM1),	and	primary	
hypogonadism.	 Commonly	 this	 endocrine	 disorder	
is	 often	 accompanied	 by	 such	 manifestations	 as	
vitiligo,	 alopecia,	 pernicious	 anemia,	 scleroderma,	
myasthenia,	 celiac	 disease,	 atrophy	 of	 the	 optic	
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nerves, etc. 3.
The	variants	of	the	APGS	of	type	2	include	the	so-
called	 Carpenter	 syndrome,	 which	 is	 characterized	
by	autoimmune	disease	of	adrenal	 (hypocorticism),	
thyroid	 gland	 (lymphocytic	 thyroiditis)	 and	 type	
1 diabetes mellitus (DM) in any combination of 
these	 symptoms	 with	 hypoparathyroidism	 and	
hypogonadism.
This	syndrome	occurs	quite	rarely	-	with	a	frequency	
of	 1.4-4.5	 cases	 per	 100	 thousand	 populations	 and	
affects	 mostly	 women.	 Carpenter	 syndrome	 is	
believed to be a genetic disorder that is inherited 
by	 the	 autosomal	 recessive	 mechanism,	 which	 is	
indicated	 by	 the	 presence	 of	 pathology	 in	 several	
generations in one family.
The	development	mechanism	of	Carpenter	syndrome	
is	associated	with	autoimmune	destructive	processes:	
the	 immune	 system	 produces	 antibodies	 and	 killer	
cells that destroy healthy body tissues. Polyglandular 
insufficiency	 develops	 as	 a	 result	 of	 an	 immunity	
attack	 on	 abnormal	 HLA	 antigens,	 which	 are	
present	 on	 the	membranes	 of	 the	 endocrine	 glands	
cells.	 Another	 aspect	 is	 the	 lack	 of	 suppressor	
T-lymphocytes	that	inadequately	suppress	antibodies	
synthesized	by	the	body’s	protective	system.
Typically,	 APGS	 type2	 manifests	 itself	 after	 30	
years	 and	 mostly	 the	 first	 time	 of	 osten	 is	 the	
development	 of	 primary	 adrenal	 insufficiency,	
which	 is	 subsequently	 joined	by	AIT	and	DM	type	
1	 (on	 average	 in	 7-10	 years).	 In	 the	 presence	 of	
chronic	adrenal	 insufficiency	(CAI)	of	autoimmune	
genesis,	about	half	of	the	patients	suffer	from	other	
autoimmune diseases.
Below is a case of self-observed Schmidt’s syndrome.
Patient К.,	36years. 
Complaints	20.12.	2016y.  - patient				36	years old, 
appealedtocomplaintsaboutchangingthecolorofth
eskin,	 reducingbodyweightby	 10	 kgin	 2	 months,	
expressedgeneralweakness,	 loweringbloodpressure,	
reducingsexualdesire.
From	the	history	of	 the	patient	 it	 is	known	that	 the	
first	 visit	 to	 the	 endocrinologist	 was 8 years ago 
(2009	y.) (at	 the	 time	the	patient	was	28	years	old)	
about	complaints	of	weight	gain	(BMI	32	kg	/	m2),	
memory	impairment,	sleep	disturbances,	decrease	in	
physical	 and	mental	 capacity,	 swelling	 on	 the	 face	
(especially	 in	 the	 morning),	 fluctuations	 in	 blood	
pressure.	The	diagnosis	was	established	8	years	ago	
(2009y.):	Autoimmune	thyroiditis,	hypotrophic	form	
with	hypofunction	of	the	thyroid	gland.	Alimentary-
constitutional obesity Ist.	Treatment	was	prescribed:	
levothyroxine	75	μg	/	day	and	metformin	1000	μg	2	
times a day.
Since	then,	the	patient	did	not	visit	the	endocrinologist	
regularly,	dose	correction	of	adjustment	levothyroxine	
was	 not	 performed,	 the	 level	 of	 TSG	 was	 not	
controled,	metformin	was	received	irregularly.
	 When	the	patient	was	32	years	old	(2013y.),	
he	 re-married	 (first	marriage	 -	 no	 children’s).	 Two	
years	 after	marriage	 (6	 years	 after	 the	 first	 visit	 to	
the	endocrinologist),	he	began	to	notice	weight	loss,	
general	weakness	 and	 rapid	 tiredness,	polyuria	 and	
polydipsia,	 decreased	 sexual	 desire	 and	 erection,	
decreased testicle size.
	 The	 second	 marriage	 -	 no	 children.	At	 an	
endocrinologist’s examination (15.02.2013),glycemia 
-	11.2	mmol	/	l,	total	cholesterol	-	5.0	mmol	/	L,	glued	
hemoglobin	 9.7%,	Anti-Islet	 Cell	 antibodies	 (ICA)	
1/126	(positive	result	>	1	/	10),	GAD-autoantibodies,	
IgG	 1/68	 (positive	 result	 >	 1/10),	 C-peptide	 -	 not	
detected,	luteinizing	hormone	(LH)	4.5	mU	/	ml	(N	
4-18),	follicle	stimulating	hormone	(FSH)	7.54	mD	
/	ml	(N	4-25),	total	testosterone	-	6.23	(N8,64	–	29	
nmol/l(15.02.2013_), sex steroid binding globulin 
(SSBG) (132	нмоль/л,	N13-71	nmol / l,	(15.02.2013), 
free testosterone 4.1 pg/ml(N	 8.8	—	 42.5	 pg/ml)), 
antibodies	to	thyroperoxidase	687	IU	/	ml	(N	to	32	
IU	 /	ml),	TSG	15.6	μM	 /	ml	 (N	0.4-4.2),	 prolactin	
9.7	 ng	 /	ml	 (N	2.6-17.2).	Cariotype:	 46	XY.	Study	
of	ejaculate:	V	1.5	ml	(N	2-5	ml),	morphologically	
normal	sperm	20%	(N>	30%),	live	-	35%	(N>	50%),	
progressive	movement	30%	(N>	50%)	.
Radiography	of	the	sellaturcica:	(19.02.2013).	
 Dimensions of the sellaturcica  9mm and 11 mm. 
(possibly	in	more	detail).
Conclusion:osteoporosis	not	found.
21.02.2013.	 Diagnosis:	 Primary	 (autoimmune)	
hypothyroidism,	 moderate	 severity,	 state	 of	
decompensation.	 Secondary	 hypogonadism.	
Diabetes	mellitus	type	1,	detected	for	the	first	time,	
state	of	decompensation.
Prescribed	 treatment:	 insulin	 therapy	 (aspart,	
648 648
Pasiechko Nadiya, Naumova Lyudmyla, Pankiv Ivan, Krytskyy Taras, Khomits Alla
degludec)	 day	 dose	 	 42	 OD,	 levothyroxine	 100	
mcgr / day, vitamin E, selenium 100 mcgr, chorionic 
gonadotrophin	 1500	 OD	 intramuscularly	 once	 per	
week,	monthly	courses	with	the	same	break.
In 4 months (21.06.2013)), the indicators of 
spermograms	has	improved	(Investigationofejaculate:	
V	1,5	мл	(N	2-5	мл),	Morphologicallynormalsperm	
32%	 (N>	 30%),	 live	 -	 51%	 (N>	 50%),	
withprogressivemovementof	50%	(N>	50%).	,	TTG	
4.2	μM	 /	ml.	Glycatedhemoglobinlevel	 8.9%,	TSG	
4.2	 μM	 /	 ml.	 Glycemiclevel	 (biforbrekfast	 4.6-5.3	
mmol / l.
It	 is	 known	 from	 a	 family	 history	 that	 a	 year	 later	
(2014y.)	a	child	was	born.
It	 is	 known	 from	 anamnesis	 that	 in	 recent	 years	
(from	2014 to	2016)	he	was	 treated	 irregularly,	 the	
last 3 months did not use levothyroxine, often did 
not administer short-acting insulin before dinner, due 
to	treguenthypoglycemia.The	worst	patient	feeling	in	
the	winter-spring	period.
At	the	moment,	 the	patient	is	36	years	old	(8	years	
after	the	first	treatment),	and	is	complaining	about	a	
change	of	the	skin	color,	a	decrease	in	body	weight	
for	10	kg	in	2	months,	a	marked	general	weakness,	a	
decrease	in	blood	pressure	and	sexual	desire.
Data	 of	 objective	 examination:	 (20.06.	 2016	 рік)	 
height	 180	 cm,	 body	 weight	 69	 kg,	 pubis	 and	
face	hairy	 is	 scanty.	BMI	21.29	kg	 /	m2.	Skin	 and	
visible	 mucous	 membranes	 are	 pure,	 pale	 pink,	
hyperpigmentation	of	 skin	and	mucous	membranes	
open	 to	 the	 sun,	 natural	 folds	 are	 hyperpigmented.	
Pulse		60	per	minute,	BP	80/50	mm	Hg.	The	activity	
of	the	heart	is	rhythmic,	the	tones	are	muffled,	pure.	
Breathing	 is	 vesicular.	Tongue	 is	wet.	Abdomen	 is	
soft,	painless.	The	liver	protrudes	from	the	edge	arc	
by	1	cm.	The	edges	are	rounded,	non-pleural	while	
palpation.	The	spleen	is	not	palpable.	No	edema.
Data of laboratory and instrumental surveys 
(20.06-27.06	 2016).	 Indicators	 of	 general	 urine	
and blood tests are normal.Glycemicprofile	 3, 
2-4,1-15,7ммоль/л,	 часті	 гіпоглікемії	 натще. At 
the	biochemical	examination	of	blood	–	 there	 is	an	
increase	in	glycemia	to	11.8	mmol,	HbA1c	-	10.6%.	
Antibodies	to	thyroperoxidase	level	-	334	IU	/	ml	(N	
to	32	IU	/	ml),	TSG	9.2	(N	0.4-4.2)	on	the	background	
of	receiving	100	μg	levothyroxine,	serum	cortisol	1.7	
μg	/	dl	(norm	6.2	-19.4	μg	/	dl),	free	testosterone	5,9	
pg	/	ml	(N	8,8-42pg/ml,5	),	total	testosterone	7,28	(N	
8,64-29	nmol/l),	SSBG97	nmol/k	(N	13-71	nmol/l).
ECG:	 sinus	 rhythm,	 wrong,	 bradycardia,	 normal	
position	 of	 the	 electric	 axis	 of	 the	 heart,	 single	
ventricular extrasystoles.
Consultation	 of	 an	 ophthalmologist:	 diabetic	
nonproliferative	retinopathy	of	both	eyes.
Consultation of the cardiologist: metabolic 
cardiomyopathy,	sinus	bradycardia,	single	ventricular	
extrasystole, CI I st.
Consultation	of	a	neurologist:	Mixed	encephalopathy	1st.
Taking	 in	 to	 account	 the	presence	of	 the	 following	
diseases	 in	 the	 patient:	 Autoimmune	 thyroiditis,	
primary	 hypothyroidism,	 moderate	 severity,	 state	
of	 decompensation.	 Secondary	 hypogonadism.	
Primary	 chronic	 adrenal	 insufficiency,	 moderate	
severity,	state	of	decompensation.	Diabetes	mellitus	
type	1,	moderate	severity,	state	of	decompensation,	
diabetic	 nonproliferative	 retinopathy	 of	 both	 eyes.	
Metabolic	cardiomyopathy,	 sinus	bradycardia,	CI	1	
st.	Mixed	encephalopathy	of	1	degree,	diagnosis	was	
established: Schmidt’s syndrome.
Prescribed	 treatment:	 hypoglycemic	 food	 with	
restriction of easily digestible carbohydrates, 
hydrocortisone	20	mg	/	day,	cortinef	0.5	mg	per	day,	
insulin	therapy:	trisiba	(deglyudec)	22:00	-	22	units	
per	 pc;	 Novarapid	 (aspart)	 before	 breakfast	 6	 OD,	
before	dinner	6	OD,	before	 supper	6	OD,	 tiocetam	
10.0	U	intravenously	1	time	a	day,	levothyroxine	125	
mg	 /	 day,	 cefazel	 100	mg	 twice	 daily,	 testosterone	
-proviron	(mesterolon)	75	mg/d.
After the therapy,	 the patient’s condition improved.	
Repeatedly the patient appeared on the review	 6	
months after treatment	(20.12.2016)
The	 patient’s	 condition	 has	 improved	 on	 the	
background	of	the	therapy.	Hyperpigmentation	of	the	
skin	and	natural	areas	of	pigmentation	are	reduced,	
there	 is	 a	 stabilization	 of	 blood	 pressure	 at	 a	 level	
of	 120	 /	 70-110	 /	 70	mm	Hg,	 reduction	 of	 clinical	
symptoms,	 achieved	 target	 level	 of	 glycemia	 and	
hormonal	blood	parameters	
thetargetglycemialevelwasreached	 (4.6-5.1	
mmol	 /	 L),	 glycosylatedhemoglobin	 (8.1%)	
andhormonalbloodparameters	 (TTG	 3.4	 mmol	
/	 L)	 cortisolserum	 1.7	 μg	 /	 dl	 (norm	 6.2-19.4	 μg	
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/	 dl),	 testosteronefree	 3.4	 pg	 /	 ml	 (N	 1.7-8.2),	
totaltestosterone	 -	 12.28	 (N	 8.64	 -	 29	 nmol	 /	 l),	
sex steroid binding globulin	 (CHD)	 (67	 nmol	 /	 l,	
attherateof		13-71	nmol	/	l,	),	testosterone free	8.9	pg	
/	ml	(N	8.8	-	42.5	pg	/	ml)
Discussion
Specific	 parameters	 of	 testosterone	 levels	
physiological	lowering	in	the	blood	vary	considerably,	
depending	 on	 age,	 ethnicity,	 and	 other	 factors.	
Usually it starts at the age of 45-50 years (rarely less 
than	30	years)	and	is	quite	slow,	namely	1-1.5%	per	
year4. As for the free fraction of testosterone, that is, 
the	physiologically	active	fraction,	it	is	reduced	twice	
as fast, ahead of an increase in the level of SSBG, 
which	is	1.3%	per	year.
The	medical	and	social	significance	of	hypogonadism	
is determined by the fact that it not only negatively 
affects	the	standard	of	living,	but	is	also	a	recognized	
risk	 factor	 for	 death,	 primarily	 of	 cardiovascular	
disease3.	 The	 development	 and	 progression	 	 of	
hypogonadism	is	influenced	by	various	concomitant	
diseases,	 among	which	 the	 leading	 role	 belongs	 to	
obesity. Literary sources indicate that a healthy 
lifestyle,	 prevention,	 and	 treatment	 of	 concomitant	
diseases	can	slow	down	the	decreasing	of	testosterone	
levels2.	 The	 direct	 relation	 to	 the	 disruption	 of	
metabolism	 with	 hypogonadism,	 especially	 the	
increase	 in	 fatty	 matter	 up	 to	 obesity,	 has	 an	
increased conversion of testosterone into estradiol, 
and endosestanol - in estrone. Estrogens stimulate the 
synthesis of SSBG in the liver, increasing its content 
in systemic circulation and binding of testosterone. 
Hence	 -	 a	 decrease	 in	 the	 active	 fraction	 of	 free	
testosteroneis	 observed,	 and	 as	 a	 consequence	 -	 an	
increase	in	androgen	deficiency.
	 According	 to	 European	 studies,	 obesity	 in	
men	may	be	due	not	only	to	the	lowering	of	testosterone	
but	 also	 to	 its	 cause.	 That	 is,	 obesity	 provokes	
testosterone	 deficiency,	 and	 testosterone	 deficiency	
leads to obesity, forming a closed circle that can only 
be	discontinued	by	substituting	testosterone.	There	is	
evidence	that	pathospermia	develops	in	patients	with	
hypofunction	of	the	thyroid	gland	on	the	background	
of	testicular	insufficiency.	In	this	case,	in	the	majority	
of	patients,	 the	hypoandrogenic	status	is	formed	by	
the	type	of	normal	anadotropic	hypogonadism,	when	
the	 levels	 of	 LH	 and	 FSH	 are	 within	 the	 normal	
range.	Most	likely,	the	violation	of	the	fertile	ability	
of	 sperm	 is	 due	 to	 the	 development	 of	 oxidative	
stress in the testicles4.	It	is	the	factor	that	explains	the	
reason	for	the	appointment	of	antioxidants.
It	 is	 known	 that	 hypothyroidism	 decreases	 the	
activity	 of	 enzymes,	 which	 are	 responsible	 for	 the	
synthesis of testosterone in the testicles3. Probably 
the	 elimination	 of	 thyroid	 hormones	 deficiency	
restores the biosynthesis of testosterone in the 
testicles.	Consequently,	the	main	factor	contributing	
to	 the	 growth	 of	 testosterone	 in	 infertile	men	with	
hypofunction	 of	 the	 thyroid	 gland	 is	 primarily	
the normalization of the thyroid status. Erectile 
dysfunction is a result of reducing the activating 
effect	 of	 testosterone	 on	 all	 levels	 of	 its	 regulation	
-	the	cerebral	cortex,	the	middle	brain,	penis	smooth	
muscle, vascular endothelium. Sexual disorders are 
deepened	by	depression,	sleep	disturbance,	memory	
loss,	 cognitive	 impairment,	 irritability.	 These	
psycho-physiological	 disorders	 are	 accompanied	
by	 increased	 fatigue,	 reduced	 physical	 and	 mental	
performance,	 a	 number	 of	 vegetative-vascular	
disorders,	 fluctuations	 of	 blood	 pressure,	 hands	
tremor,	and	increased	sweating.	
The	presence	of	vitiligo	in	patients	may	serve	as	an	
additional	 marker	 for	 the	 presence	 of	 concomitant	
diseases of the autoimmune genes.
In the case of diagnosing one of the autoimmune 
diseases, the clinician should be careful about the 
spread	 of	 autoimmune	 damage	 to	 other	 endocrine	
glands,	which	may	develop	not	simultaneously,	but	
for a long time.
	 In	case	of	APGS	suspicion,	it	is	necessary	to	
determine	immediately	in	patients	levels	of	antibodies	
to	 thyroperoxidase,	 antibodies	 to	 thyroglobulin,	
antibodies	to	beta-cells	of	the	pancreas	and	conduct	
screening tests for the detection of allergies. In 
the	 treatment	 of	 APGS	 (in	 particular	 Schmidt’s	
syndrome),	 it	 is	 necessary	 to	 carry	 out	 a	 complex	
continuous	 treatment	 of	 hypothyroidism,	 chronic	
adrenal	 insufficiency,	 and	 type	 1	 diabetes	 until	
complete	compensation	is	obtained.
Conclusions
1.Incouse diagnostic one of autoimmune diseases 
doctor must has be alertness about distribute 
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autoimmune	 damage	 endocrine	 glands,	 which	 can	
develop	not	at	the	moment	but	during	long	time.
2.	Decompensation	of	adrenal	insufficiency	(decrease	
in glucocorticoids as contrinsular hormone) 
Can	 lead	 to	 untypical	 course	 of	 diabetes	 with	
steaolyhipoglicemia	in	autumne-summer	period	and	
normalizabionglycemia	in	winter-autumne	period.
3.	 Predisposition	 to	 hypoglicemia	 at	 high	 level	
glycosylated hemoglobin must setting doctor in 
diagnostic	search	about	adrenal	insufficiency.
4.	Presents	of	2-3	decompensatee,endocrine	diseases	
in	the	same	moment	suppresses		pronounced	typical	
symptomatics	each	of	them	proceeds	with	erased	or	
disguised	picture.
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